Mandate

Vinge advises Oncorena

January 13, 2022

Vinge advises Oncorena Holding AB in connection with an investment of initially SEK 66 million from Linc, HealthCap and Fåhraeus Startup and Growth.

The investment will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients with advanced kidney cancer. In the event that the initial part of the clinical study provides positive results, the investors intend to finance the second part of the study with an additional SEK 94 million.

 

The Vinge team includes Christian Lindhé, Martin Svanberg and Sofie Nordgren.

Related

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025